An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Zhang, Huagang ^a   Liu, Laibin ^a   Yu, Dong ^b   Kandimalla, Ekambar R ^b   Sun, Hui Bin ^a   Agrawal, Sudhir ^b   Guha, Chandan ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b HYBRIDON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE ACTIVATION; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER INFILTRATION; CANCER INHIBITION; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL EXPANSION; CHEMORADIOTHERAPY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNOFLUORESCENCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LEWIS CARCINOMA; LUNG ADENOCARCINOMA; LUNG METASTASIS; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; SURVIVAL RATE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MODEL; WILD TYPE; ADENOCARCINOMA; ANIMAL; B LYMPHOCYTE; DENDRITIC CELL; DISEASE COURSE; DRUG EFFECT; DRUG POTENTIATION; HUMAN; IMMUNOLOGY; LUNG TUMOR; METASTASIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIATION EXPOSURE; RECURRENT DISEASE; SURVIVAL; TUMOR CELL LINE; TUMOR MICROENVIRONMENT; VACCINATION;

MURINAE; MUS;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DISEASE PROGRESSION; HUMANS; IMMUNOMODULATION; LUNG NEOPLASMS; MALE; MICE; NEOPLASM METASTASIS; RECURRENCE; SURVIVAL ANALYSIS; TOLL-LIKE RECEPTOR 9; TUMOR MICROENVIRONMENT; VACCINATION;

EID: 84861630513     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038111     Document Type: Article

References (39)

1. Lichter AS, Lawrence TS, (1995) Recent advances in radiation oncology. N Engl J Med 332: 371-379.
2. Sutherland RM, (2006) Radiation-enhanced immune response to cancer: workshop, Anaheim, CA, April 17, 2005. Int J Radiat Oncol Biol Phys 64: 3-5.
3. Friedman EJ, (2002) Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 8: 1765-1780.
4. McBride WH, Chiang CS, Olson JL, Wang CC, Hong JH, et al. (2004) A sense of danger from radiation. Radiat Res 162: 1-19.
5. Stevenson FK, Johnson PW, (2010) Harnessing innate immunity to suppress lymphoma. J Clin Oncol 28: 4295-4296.
6. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, et al. (2006) Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 203: 1259-1271.
7. Chiriva-Internati M, Grizzi F, Pinkston J, Morrow KJ, D'Cunha N, et al. (2006) Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors. In Vitro Cell Dev Biol Anim 42: 89-95.
8. Matsumura S, Wang B, Kawashima N, Braunstein S, Badura M, et al. (2008) Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol 181: 3099-3107.
9. Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, et al. (2008) Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol 180: 3132-3139.
10. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, et al. (2004) External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 64: 4328-4337.
11. Demaria S, Bhardwaj N, McBride WH, Formenti SC, (2005) Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 63: 655-666.
12. Krieg AM, (2008) Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27: 161-167.
13. Akira S, Uematsu S, Takeuchi O, (2006) Pathogen recognition and innate immunity. Cell 124: 783-801.
14. Latz E, Verma A, Visintin A, Gong M, Sirois CM, et al. (2007) Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Nat Immunol 8: 772-779.
15. Iwasaki A, Medzhitov R, (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5: 987-995.
16. Chaudhry U, Kingham P, Plitas G, Katz S, Stabelford J, et al. (2006) Interleukin-18 and the toll-like receptor 9 ligand CpG stimulate murine splenic natural killer dendritic cells (NKDC) to proliferate and secrete IFN-gamma. Journal of the American College of Surgeons 203: S79-S80.
17. Chaudhry UI, Kingham TP, Plitas G, Katz SC, Raab JR, et al. (2006) Combined Stimulation with Interleukin-18 and CpG Induces Murine Natural Killer Dendritic Cells to Produce IFN-{gamma} and Inhibit Tumor Growth. Cancer Res 66: 10497-10504.
18. Krieg AM, (2006) Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5: 471-484.
19. Aurisicchio L, Peruzzi D, Conforti A, Dharmapuri S, Biondo A, et al. (2009) Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9. Clin Cancer Res 15: 1575-1584.
20. Chiron D, Bekeredjian-Ding I, Pellat-Deceunynck C, Bataille R, Jego G, (2008) Toll-like receptors: lessons to learn from normal and malignant human B cells. Blood 112: 2205-2213.
21. Damiano V, Caputo R, Garofalo S, Bianco R, Rosa R, et al. (2007) TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. Proc Natl Acad Sci U S A 104: 12468-12473.
22. Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, et al. (2000) Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 164: 1617-1624.
23. Kandimalla ER, Bhagat L, Li Y, Yu D, Wang D, et al. (2005) Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent Toll-like receptor 9 agonists. Proceedings of the National Academy of Sciences of the United States of America 102: 6925-6930.
24. Kandimalla ER, Bhagat L, Wang D, Yu D, Zhu FG, et al. (2003) Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. Nucleic Acids Res 31: 2393-2400.
25. Wang D, Kandimalla ER, Yu D, Tang JX, Agrawal S, (2005) Oral administration of second-generation immunomodulatory oligonucleotides induces mucosal Th1 immune responses and adjuvant activity. Vaccine 23: 2614-2622.
26. Wang H, Rayburn ER, Wang W, Kandimalla ER, Agrawal S, et al. (2006) Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9. Molecular Cancer Therapeutics 5: 1585-1592.
27. Wang D, Li Y, Yu D, Song SS, Kandimalla ER, et al. (2004) Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs. Int J Oncol 24: 901-908.
28. Cerkovnik P, Novakovic BJ, Stegel V, Novakovic S, (2010) Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity. BMC Immunol 11: 45.
29. Chamoto K, Takeshima T, Wakita D, Ohkuri T, Ashino S, et al. (2009) Combination immunotherapy with radiation and CpG-based tumor vaccination for the eradication of radio- and immuno-resistant lung carcinoma cells. Cancer Sci 100: 934-939.
30. Mason KA, Ariga H, Neal R, Valdecanas D, Hunter N, et al. (2005) Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res 11: 361-369.
31. Milas L, Mason KA, Ariga H, Hunter N, Neal R, et al. (2004) CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res 64: 5074-5077.
32. Yu D, Kandimalla ER, Bhagat L, Tang JY, Cong Y, et al. (2002) 'Immunomers'-novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Nucleic Acids Res 30: 4460-4469.
33. Jager E, Stockert E, Zidianakis Z, Chen YT, Karbach J, et al. (1999) Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. Int J Cancer 84: 506-510.
34. Kandimalla ER, Bhagat L, Zhu FG, Yu D, Cong YP, et al. (2003) A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif. Proc Natl Acad Sci U S A 100: 14303-14308.
35. Pillarisetty VG, Katz SC, Bleier JI, Shah AB, Dematteo RP, (2005) Natural killer dendritic cells have both antigen presenting and lytic function and in response to CpG produce IFN-gamma via autocrine IL-12. J Immunol 174: 2612-2618.
36. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, et al. (2009) Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 15: 5379-5388.
37. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, et al. (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13: 54-61.
38. Hodge JW, Guha C, Neefjes J, Gulley JL, (2008) Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park) 22: 1064-1070; discussion 1075, 1080-1061, 1084.
39. Saha S, Bhanja P, Liu L, Alfieri AA, Yu D, et al. (2012) TLR9 agonist protects mice from radiation-induced gastrointestinal syndrome. PLoS One 7: e29357.